Summary

The global CGRP Inhibitors Market is experiencing a significant transformation as the demand for targeted and effective migraine treatments continues to grow. According to the latest projections, the market is expected to expand from US$ 5.9 Bn in 2025 to an impressive US$ 11.4 Bn by 2032, progressing at a robust CAGR of 9.7%. This surge is attributed to increased patient awareness, advances in treatment modalities, and the growing preference for CGRP antagonists and monoclonal antibodies over traditional migraine therapies.

Market Insights

CGRP inhibitors, which target the calcitonin gene-related peptide involved in migraine pathophysiology, are gaining traction globally for their safety, efficacy, and targeted mechanism of action. These therapies provide an alternative to older treatments such as triptans and painkillers, which are often associated with side effects and require multiple dosages. As a result, both patients and healthcare professionals are increasingly favoring CGRP inhibitors for preventive and acute migraine management.

Recent clinical studies underscore the efficacy of CGRP inhibitors in reducing both the frequency and severity of migraine attacks. Many patients report improvements within the first month of use, making these treatments particularly appealing for those with chronic or refractory migraines. Furthermore, ongoing development of oral CGRP inhibitors provides easier administration options, expanding the potential user base.

Market Drivers

A key driver behind the widespread adoption of CGRP inhibitors is their rapid onset of action and sustained efficacy. Traditional therapies often come with limitations such as slower symptom relief and the risk of medication overuse headaches. In contrast, CGRP inhibitors offer a more targeted approach, reducing the biological triggers of migraines and providing long-term relief. These benefits are reshaping treatment preferences and bolstering the global CGRP inhibitors market.

Additionally, the rising prevalence of migraines, particularly among adolescents and working professionals, is propelling demand. With migraine ranking among the leading causes of disability worldwide, there is a growing emphasis on more reliable, long-term treatment options that do not compromise quality of life. The availability of CGRP therapies through hospital, retail, and online pharmacies further supports accessibility and uptake.

Business Opportunity

A major opportunity lies in the expansion of CGRP inhibitor indications to include pediatric and adolescent populations. As clinical trials continue to yield positive results in younger patients, pharmaceutical companies are exploring ways to broaden the approved age groups. Moreover, faster regulatory approvals in key markets such as the U.S. and Europe have enabled quicker launches, making these therapies more accessible to patients in need.

Emerging markets, especially in the Asia Pacific region, also present a vast growth opportunity. The increasing burden of migraines in developing economies, coupled with improving healthcare infrastructure, is creating favorable conditions for market expansion. The future introduction of CGRP biosimilars is expected to lower treatment costs, making these advanced therapies more affordable and widely available.

Challenges and Barriers

Despite the positive outlook, the high cost of CGRP inhibitors remains a substantial barrier to market growth. With monthly prices often exceeding $500–$600 without insurance, affordability is a key concern, especially in low- and middle-income regions. Even in developed countries, restrictive insurance policies and high co-pays limit patient access. Many insurance providers require patients to exhaust conventional therapies before approving CGRP treatment, delaying effective care.

In Europe and other developed markets, CGRP inhibitors are typically reserved for severe cases, further restricting patient eligibility. In emerging markets, limited public healthcare coverage and out-of-pocket costs deter many from choosing these treatments. Until the pricing becomes more competitive or broader insurance coverage is achieved, the full potential of the CGRP inhibitors market may not be realized.

Regional Analysis

North America currently dominates the global CGRP inhibitors market, driven by high diagnosis rates, advanced healthcare systems, and substantial patient awareness. In the U.S., a large number of neurologists and headache specialists, along with relatively faster regulatory approvals, contribute to early adoption of novel therapies. Pharmaceutical companies have also prioritized the North American market for drug launches and clinical trials, further strengthening the region’s leadership.

Asia Pacific, on the other hand, is anticipated to witness the highest CAGR during the forecast period. Countries like India, China, and Japan are seeing a rise in migraine prevalence due to factors such as stress, environmental changes, and lifestyle modifications. A 2024 study in the Journal of Population Therapeutics and Clinical Pharmacology found that stress, weather changes, and sleep deprivation are key migraine triggers in the Indian population. This rising burden is expected to fuel demand for effective treatments, with CGRP inhibitors positioned to capture a significant share of the market in the region.

Europe remains a strong market, although access is often governed by national health policies. Latin America and the Middle East & Africa are emerging as regions with future growth potential, particularly as awareness improves and healthcare access expands.

Competitive Analysis

The CGRP inhibitors market is highly competitive, with leading pharmaceutical companies investing in research and strategic partnerships to strengthen their portfolios. Key players include Pfizer Inc., AbbVie Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Lundbeck A/S, and Amgen Inc. These companies have launched several FDA-approved therapies targeting both acute and preventive migraine treatment.

Competition is further fueled by ongoing innovations aimed at enhancing drug efficacy, reducing side effects, and simplifying administration. Companies are also exploring co-development agreements and collaborations with healthcare providers to improve patient outreach and education.

As more players enter the space and biosimilars emerge, price competition is expected to intensify, ultimately improving affordability and access across global markets.

Global CGRP Inhibitors Market Segmentation

By Drug Type

• Monoclonal Antibodies

• CGRP Antagonists

By Treatment Type

• Acute (Abortive)

• Preventative

By Route of Administration

• Oral

• Injectable

• Nasal

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Patient Demographics

• Adult

• Geriatric

• Pediatric

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global CGRP Inhibitors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. List of Recent FDA-Approved CGRP Inhibitors
2.5. Pipeline Assessment
2.6. Prevalence of Migraine by Key Countries
2.7. Reimbursement Scenario
2.8. Porter’s Five Forces Analysis
2.9. COVID-19 Impact Analysis
2.9.1. Supply
2.9.2. Demand
2.10. Impact of Ukraine-Russia Conflict
2.11. Economic Overview
2.11.1. World Economic Projections
2.12. PESTLE Analysis
3. Global CGRP Inhibitors Market Outlook, 2019-2032
3.1. Global CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Monoclonal Antibodies
3.1.1.2. CGRP Antagonists
3.2. Global CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Acute (Abortive)
3.2.1.2. Preventative
3.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Injectable
3.3.1.3. Nasal
3.4. Global CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.4.1.3. Online Pharmacies
3.5. Global CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. Adult
3.5.1.2. Geriatric
3.5.1.3. Paediatric
3.6. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America CGRP Inhibitors Market Outlook, 2019-2032
4.1. North America CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Monoclonal Antibodies
4.1.1.2. CGRP Antagonists
4.2. North America CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Acute (Abortive)
4.2.1.2. Preventative
4.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Injectable
4.3.1.3. Nasal
4.4. North America CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.1.3. Online Pharmacies
4.5. North America CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. Adult
4.5.1.2. Geriatric
4.5.1.3. Paediatric
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.6.1. Key Highlights
4.6.1.1. U.S. CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
4.6.1.2. U.S. CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
4.6.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
4.6.1.4. U.S. CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.6.1.5. U.S. CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
4.6.1.6. Canada CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
4.6.1.7. Canada CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
4.6.1.8. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
4.6.1.9. Canada CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.6.1.10. Canada CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe CGRP Inhibitors Market Outlook, 2019-2032
5.1. Europe CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Monoclonal Antibodies
5.1.1.2. CGRP Antagonists
5.2. Europe CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Acute (Abortive)
5.2.1.2. Preventative
5.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Injectable
5.3.1.3. Nasal
5.4. Europe CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. Online Pharmacies
5.5. Europe CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Adult
5.5.1.2. Geriatric
5.5.1.3. Paediatric
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.6.1. Key Highlights
5.6.1.1. Germany CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.2. Germany CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.4. Germany CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.5. Germany CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.6. U.K. CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.7. U.K. CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.8. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.9. U.K. CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.10. U.K. CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.11. France CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.12. France CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.13. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.14. France CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.15. France CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.16. Italy CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.17. Italy CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.18. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.19. Italy CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.20. Italy CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.21. Turkey CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.22. Turkey CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.23. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.24. Turkey CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.25. Turkey CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.26. Russia CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.27. Russia CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.28. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.29. Russia CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.30. Russia CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.1.31. Rest of Europe CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
5.6.1.32. Rest of Europe CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
5.6.1.33. Rest of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
5.6.1.34. Rest of Europe CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.6.1.35. Rest of Europe CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific CGRP Inhibitors Market Outlook, 2019-2032
6.1. Asia Pacific CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Monoclonal Antibodies
6.1.1.2. CGRP Antagonists
6.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Acute (Abortive)
6.2.1.2. Preventative
6.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Injectable
6.3.1.3. Nasal
6.4. Asia Pacific CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. Online Pharmacies
6.5. Asia Pacific CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. Adult
6.5.1.2. Geriatric
6.5.1.3. Paediatric
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.6.1. Key Highlights
6.6.1.1. China CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.2. China CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.4. China CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.5. China CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.1.6. Japan CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.7. Japan CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.8. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.9. Japan CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.10. Japan CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.1.11. South Korea CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.12. South Korea CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.13. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.14. South Korea CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.15. South Korea CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.1.16. India CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.17. India CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.18. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.19. India CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.20. India CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.1.21. Southeast Asia CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.22. Southeast Asia CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.23. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.24. Southeast Asia CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.25. Southeast Asia CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.1.26. Rest of Asia Pacific CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
6.6.1.27. Rest of Asia Pacific CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
6.6.1.28. Rest of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
6.6.1.29. Rest of Asia Pacific CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.6.1.30. Rest of Asia Pacific CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America CGRP Inhibitors Market Outlook, 2019-2032
7.1. Latin America CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Monoclonal Antibodies
7.1.1.2. CGRP Antagonists
7.2. Latin America CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Acute (Abortive)
7.2.1.2. Preventative
7.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Injectable
7.3.1.3. Nasal
7.4. Latin America CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. Online Pharmacies
7.5. Latin America CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Adult
7.5.1.2. Geriatric
7.5.1.3. Paediatric
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.6.1. Key Highlights
7.6.1.1. Brazil CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
7.6.1.2. Brazil CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
7.6.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
7.6.1.4. Brazil CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.6.1.5. Brazil CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
7.6.1.6. Mexico CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
7.6.1.7. Mexico CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
7.6.1.8. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
7.6.1.9. Mexico CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.6.1.10. Mexico CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
7.6.1.11. Argentina CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
7.6.1.12. Argentina CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
7.6.1.13. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
7.6.1.14. Argentina CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.6.1.15. Argentina CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
7.6.1.16. Rest of Latin America CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
7.6.1.17. Rest of Latin America CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
7.6.1.18. Rest of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
7.6.1.19. Rest of Latin America CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.6.1.20. Rest of Latin America CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa CGRP Inhibitors Market Outlook, 2019-2032
8.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Monoclonal Antibodies
8.1.1.2. CGRP Antagonists
8.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Acute (Abortive)
8.2.1.2. Preventative
8.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Injectable
8.3.1.3. Nasal
8.4. Middle East & Africa CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. Online Pharmacies
8.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. Adult
8.5.1.2. Geriatric
8.5.1.3. Paediatric
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.6.1. Key Highlights
8.6.1.1. GCC CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
8.6.1.2. GCC CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
8.6.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
8.6.1.4. GCC CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.6.1.5. GCC CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
8.6.1.6. South Africa CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
8.6.1.7. South Africa CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
8.6.1.8. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
8.6.1.9. South Africa CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.6.1.10. South Africa CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
8.6.1.11. Egypt CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
8.6.1.12. Egypt CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
8.6.1.13. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
8.6.1.14. Egypt CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.6.1.15. Egypt CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
8.6.1.16. Nigeria CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
8.6.1.17. Nigeria CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
8.6.1.18. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
8.6.1.19. Nigeria CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.6.1.20. Nigeria CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
8.6.1.21. Rest of Middle East & Africa CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
8.6.1.22. Rest of Middle East & Africa CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
8.6.1.23. Rest of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
8.6.1.24. Rest of Middle East & Africa CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.6.1.25. Rest of Middle East & Africa CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2025
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Pfizer Inc.
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. AbbVie Inc.
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. Eli Lilly and Company
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Teva Pharmaceutical Industries Ltd.
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Lundbeck A/S
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Amgen Inc.
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations